Dividing the stage III serous carcinoma cohort according to median MAL2 or TPD52 SPC tumour values indicated similar overall survival according to MAL2 staining (Fig. 4a), but a trend towards improved overall survival with increased TPD52 staining (Fig. 4b). The gene discussed is TPD52; the disease is serous adenocarcinoma.